ClinVar Miner

Submissions for variant NM_000138.4(FBN1):c.3392A>G (p.Asn1131Ser) (rs397515790)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000035168 SCV000058810 likely pathogenic Marfan syndrome 2017-05-18 criteria provided, single submitter clinical testing The p.Asn1131Ser variant in FBN1 has been reported in 1 Caucasian individual wit h Marfan syndrome, was found to have occurred de novo, and segregated with disea se in 1 affected relative (Lerner-Ellis 2014, LMM data, pers. comm.). It has not been identified in large population studies. Additional amino acid changes at t his position (p.Asn1131Tyr, p.Asn1131Lys) were identified in at least 2 individu als with Marfan syndrome (Godfrey 1995, Wang 1997, Stheneur 2009). In vitro func tional studies provide some evidence that the p.Asn1131Ser variant may result in a protein folding defect (Whiteman 2007); however, this in vitro assay may not accurately represent biological function. Computational prediction tools and con servation analyses suggest that the p.Asn1131Ser variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, although additional studies are required to fully establish its clinic al significance, the p.Asn1131Ser variant is likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.